Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Less than a day after the US Food and Drug Administration granted emergency use authorization to Abbott for its rapid COVID-19 antigen test, the federal government has agreed to buy 150 million of them.
Abbott’s $5 point-of-care BinaxNOW COVID-19 Ag Card detects SARS-CoV-2, the virus that causes COVID-19. It’s intended for people suspected of having the virus within the first seven days of symptom onset. (See sidebar story.)
The company will be paid $760m for the tests under a contract with the Department of Health and Human Services (HHS) and the Department of Defense.
BinaxNOW uses lateral flow technology to test nasal-swab samples on a device the size of a credit card and produces a result in roughly 15 minutes, Abbott says. The test doesn’t require any other equipment to process samples or read results, and uses only a “minimal” amount of chemical reagents.
The HHS says the tests “will be potentially deployed to schools and to assist with serving other special needs populations.”
“By strategically distributing 150 million of these tests to where they’re needed most, we can track the virus like never before and protect millions of Americans at risk in especially vulnerable situations,” HHS secretary Alex Azar said in a 27 August statement.
Abbott says it has invested “hundreds of millions of dollars” since April in two new US facilities to manufacture BinaxNOW. The company plans to ramp up production to 50 million tests a month by the beginning of October.
Medtech Insight: global medical technology news & analysis
By Ashley Yeo 27 May 2022
The EU’s full implementation of the In Vitro Diagnostic Regulation on 26 May has put the Swiss IVD industry on...
Medtech Insight: global medical technology news & analysis
26 May 2022
CorneaGen has issued an urgent recall of its Scleral Patch Grafts after discovering they were created using tissue from a...
Medtech Insight: global medical technology news & analysis
By Shawn Schmitt 26 May 2022
The US agency said on 26 May that the Dragonfly OpStar imaging catheter was recalled by the company because of...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
